2008 ICD-9-CM Volume 1 Diagnosis Codes Home > Neoplasms 140-239 > Neoplasms Of Uncertain Behavior 235-238 >
 Neoplasm of uncertain behavior of other and unspecified sites and tissues- 238 is a non-specific code that cannot be used to specify a diagnosis
Neoplasm of uncertain behavior of bone and articular cartilage- 238.0 is a specific code that can be used to specify a diagnosis
- 238.0 contains 5 index entries
Neoplasm of uncertain behavior of connective and other soft tissue- 238.1 is a specific code that can be used to specify a diagnosis
- 238.1 contains 15 index entries
Neoplasm of uncertain behavior of skin- 238.2 is a specific code that can be used to specify a diagnosis
- 238.2 contains 2 index entries
Neoplasm of uncertain behavior of breast- 238.3 is a specific code that can be used to specify a diagnosis
- 238.3 contains 1 index entry
Polycythemia vera- A chronic myeloproliferative disorder characterized by an increased red blood cell production. Excessive proliferation of the myeloid lineage is observed as well. The major symptoms are related to hypertension or to vascular abnormalities caused by the increased red cell mass. The cause is unknown. With currently available treatment, the median survival exceeds 10 years. (WHO, 2001) -- 2003
- A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.
- 238.4 is a specific code that can be used to specify a diagnosis
- 238.4 contains 7 index entries
Neoplasm of uncertain behavior of histiocytic and mast cells- A nodule of mast cells. Mastocytomas can involve the skin, subcutaneous tissue, and sometimes muscle. Also called a mast cell tumor.
- A solid tumor consisting of a dense infiltration of MAST CELLS. It is generally benign.
- 238.5 is a specific code that can be used to specify a diagnosis
- 238.5 contains 3 index entries
Neoplasm of uncertain behavior of plasma cells- (PLAS-ma-sye-TOE-ma) Cancer of the plasma cells (white blood cells that produce antibodies) that may turn into multiple myeloma.
- A malignant (clonal) proliferation of plasma cells that are cytologically and immunophenotypically identical to those of plasma cell myeloma, but manifest a localized osseous or extraosseous growth pattern. (WHO, 2001) -- 2003
- Any discrete, presumably solitary, mass of neoplastic plasma cells either in bone marrow or various extramedullary sites.
- 238.6 is a specific code that can be used to specify a diagnosis
- 238.6 contains 4 index entries
Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues- (MYE-eh-lo-dis-PLAS-tik SIN-drome) Disease in which the bone marrow does not function normally.
- A chronic myeloproliferative disorder characterized by bone marrow fibrosis, proliferation of atypical megakaryocytes and granulocytes in the bone marrow, anemia, splenomegaly, and extramedullary hematopoiesis. The cause is unknown. The median survival time is 3-5 years from diagnosis. (WHO, 2001) -- 2003
- A chronic myeloproliferative disorder that involves primarily the megakaryocytic lineage and it is characterized by sustained thrombocytosis in the blood, increased numbers of large, mature megakaryocytes in the bone marrow, and episodes of thrombosis and/or hemorrhage. The cause is unknown. Median survival times of 10-15 years are commonly reported. (WHO, 2001) -- 2003
- A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
- A clonal (malignant) proliferation of myeloid (erythroid, granulocytic, or megakaryocytic) cells originating from a primitive stem cell. -- 2003
- A disorder characterized by proliferation of lymphocytes at various stages of differentiation. Lymphoproliferative disorders can be neoplastic (clonal, as in lymphomas and leukemias) or reactive (polyclonal, as in infectious mononucleosis). --2004
- A disorder in which the bone marrow is replaced by fibrous tissue.
- A progressive disease in which the bone marrow is replaced by fibrous tissue and is unable to produce red blood cells; the cause is unknown.
- Abnormal bone marrow cells that may lead to myelogenous leukemia.
- An acute myeloid leukemia characterized by bone marrow fibrosis. The prognosis is usually poor. (WHO, 2001) -- 2003
- An increased number of thrombocytes (platelets) in the blood, without a known cause.
- Chronic myeloproliferative disorders (CMPDs) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages. The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood. CMPDs are primarily diseases of adults. -- 2003
- Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
- Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
- Conditions in which the bone marrow shows qualitative and quantitative changes suggestive of a preleukemic process, but having a chronic course that does not necessarily terminate as acute leukemia.
- Diseases in which cells of the lymphatic system grow excessively. These disorders are often treated like cancer.
- Diseases in which too many blood cells are made in the bone marrow.
- Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
- Disorders in which one or more stimuli cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential.
- Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. MDS may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001) -- 2003
- 238.7 is a non-specific code that cannot be used to specify a diagnosis
Essential thrombocythemia- 238.71 is a specific code that can be used to specify a diagnosis
- 238.71 contains 8 index entries
Low grade myelodysplastic syndrome lesions- 238.72 is a specific code that can be used to specify a diagnosis
- 238.72 contains 12 index entries
High grade myelodysplastic syndrome lesions- 238.73 is a specific code that can be used to specify a diagnosis
- 238.73 contains 6 index entries
Myelodysplastic syndrome with 5q deletion- 238.74 is a specific code that can be used to specify a diagnosis
- 238.74 contains 2 index entries
Myelodysplastic syndrome, unspecified- 238.75 is a specific code that can be used to specify a diagnosis
- 238.75 contains 3 index entries
Myelofibrosis with myeloid metaplasia- 238.76 is a specific code that can be used to specify a diagnosis
- 238.76 contains 6 index entries
Other lymphatic and hematopoietic tissues- 238.79 is a specific code that can be used to specify a diagnosis
- 238.79 contains 12 index entries
Neoplasm of uncertain behavior of other specified sites- 238.8 is a specific code that can be used to specify a diagnosis
Neoplasm of uncertain behavior site unspecified- 238.9 is a specific code that can be used to specify a diagnosis
- 238.9 contains 1 index entry
|
|
|
